

Sofracort®

framycetin/gramicidin/dexamethasone Eye/Ear drops

Resolution:

The shortage of framycetin/gramicidin/ dexamethasone (5 mg-0.05 mg-0.5 mg/mL) eye/ear drops (Sofracort®) has been resolved by the manufacturer.

Practice Implications:

Clinicians can continue to prescribe Sofracort® eye/ear drops as clinically appropriate.

Thank you to NH staff and physicians for your patience during this shortage.

Date: September 23, 2022

| Drug Shortage Resolution | |
|--------------------------|--|
| Drug Discontinuation | |
| Medication Change | |
| Best Practice | |

For the information of physicians, nurses, and pharmacists.

For further information please contact the NH Medication Use Management Pharmacists:

mumpharmacist@northernhealth.ca

PLEASE POST

